P.A.W. Capital Corp Cue Biopharma, Inc. Transaction History

P.A.W. Capital Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$2.41 - $3.74 $72,300 - $112,200	-30,000 Reduced 16.67%	150,000 $535,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $47,800 - $79,000	-20,000 Reduced 10.0%	180,000 $513,000
Q3 2022 Nov 01, 2022	BUY	$2.23 - $3.37 $55,750 - $84,250	25,000 Added 14.29%	200,000 $446,000
Q2 2022 Jul 13, 2022	BUY	$2.49 - $5.92 $62,250 - $148,000	25,000 Added 16.67%	175,000 $436,000
Q1 2022 Apr 21, 2022	BUY	$4.41 - $12.28 $132,300 - $368,400	30,000 Added 25.0%	150,000 $732,000
Q4 2021 Feb 10, 2022	SELL	$10.86 - $17.85 $54,300 - $89,250	-5,000 Reduced 4.0%	120,000 $1.36 Million
Q2 2021 Aug 05, 2021	SELL	$10.9 - $14.53 $163,500 - $217,950	-15,000 Reduced 10.71%	125,000 $1.46 Million
Q4 2020 Feb 11, 2021	BUY	$11.12 - $16.4 $1.56 Million - $2.3 Million	140,000 New	140,000 $1.75 Million
Q4 2018 Feb 06, 2019	SELL	$4.35 - $8.73 $348,000 - $698,400	-80,000 Closed	0 $0
Q3 2018 Oct 24, 2018	BUY	$7.91 - $11.89 $395,500 - $594,500	50,000 Added 166.67%	80,000 $724,000
Q1 2018 Apr 26, 2018	BUY	$11.63 - $17.25 $348,900 - $517,500	30,000 New	30,000 $422,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of P.A.W. Capital Corp, based on Form 13F filings with the SEC.

Stay updated on P.A.W. Capital Corp with notifications on news.